NASDAQ · IMNM
Immunome, Inc.
$18.29-$0.47 (-2.51%)
Immunome, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.16% below the high.
Loading market information…
NASDAQ · AURA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Aura Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.01% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Aura Biosciences, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.37. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aura Biosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 24, 2025 |
| -$0.52-20.93% vs estimate |
| $0.00 |
| Q3 2024 | Nov 12, 2024 | -$0.42+4.55% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $17.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$18.29-$0.47 (-2.51%)
Immunome, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.16% below the high.
$16.85+$0.03 (+0.18%)
Aktis Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.72% below the high.
$8.24+$0.26 (+3.26%)
Oculis Holding AG’s quoted price sits in the lower half of its reported 52-week range, 76.1% below the high.
$3.82-$0.06 (-1.55%)
Bicycle Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 57.93% below the high.
$0.74-$0.03 (-4.15%)
Ocugen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.74% below the high.
$3.30-$0.16 (-4.62%)
Whitehawk Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 40.0% below the high.
$2.38-$0.09 (-3.64%)
MacroGenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.15% below the high.
$0.49-$0.05 (-9.43%)
Outlook Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.57% below the high.
